SCHEMBL2531567

SCHEMBL2531567

CC(=O)OCCn1cc(-c2ccc(=O)n(Cc3cccc(-c4ncc(OCCN5CCOCC5)cn4)c3)n2)cn1

nearest known ligand 0.66

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ MET P08581 19/20 0.66
▸ NQO2 P16083 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2456034 0.92 MET (0.69) METNQO2
SCHEMBL3091288 0.91 MET (0.70) METNQO2
SCHEMBL2463532 0.91 MET (0.70) METNQO2
SCHEMBL2460056 0.90 MET (0.71) METNQO2
Emd-1204831 SCHEMBL2350245 0.88 MET (0.75) METNQO2
Emd-1204831 SCHEMBL2346403 0.86 MET (0.70) METNQO2
Emd-1204831 SCHEMBL2348922 0.86 MET (0.71) METNQO2
Emd-1204831 SCHEMBL2347708 0.86 MET (0.71) METNQO2
SCHEMBL3088037 0.85 MET (0.69) METNQO2
SCHEMBL3089537 0.82 MET (0.60) MET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8637518-B2 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2014-01-28 — — US disclosed
US-8637518-B2 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2014-01-28 — — US disclosed
US-8637518-B2 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2014-01-28 — — US disclosed
US-20110257181-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-10-20 — — US disclosed
US-20110257181-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-10-20 — — US disclosed
US-20110257181-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-10-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257181-A1 PYRIDAZINONE DERIVATIVES MET, TYRO3, ERBB2 MET 1/4885NQO2 600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback